Clinical trial · Observational
Strength, Aging, and Memory in Prostate Cancer
Strength, Aging, and Memory in Prostate Cancer: A Prospective Study of the Effects of Androgen Deprivation on Neurocognition and Frailty
NCT04852224CI-TRIAL-00080862STAMPcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The objective of this study is to compare changes in neurocognitive function across a 12-month period between three groups: (1) men treated with androgen deprivation therapy (ADT) for prostate cancer (PCa); (2) men under active surveillance for PCa; and (3) men without a history of cancer.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
| Prostate Neoplasm | Prostate Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (3)
- label
- Androgen Deprivation Therapy (ADT+)
- description
- Men diagnosed with prostate cancer and scheduled to receive greater than or equal to 6-months of treatment with androgen deprivation therapy
- label
- Prostate Cancer Surveillance (ADT-)
- description
- Men diagnosed with prostate cancer under active surveillance (i.e., not receiving active treatment for prostate cancer)
- label
- Non-cancer Control (PCa-)
- description
- Age-matched men without a history of cancer
Primary outcomes (12)
- measure
- Change in inhibitory control
- timeFrame
- Baseline (M0), 6-month follow-up (M6), 12-month follow-up (M12)
- description
- Change in interference score on Stroop task, with negative values indicating lower inhibitory control. The Stroop task interference score is a continuous variable with no minimum or maximum value.
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 19 Years
Show eligibility criteria text
Inclusion Criteria: * Telephone Interview of Cognitive Status (TICS-M) performance above impaired range (≥21) Group-specific criteria: * First time, primary diagnosis of prostate cancer (ADT+ and ADT-) * Diagnosed within past 30 days (ADT-) * Scheduled to receive ≥ 6-months androgen deprivation therapy and have not received \>30 days of androgen deprivation therapy (ADT+) * Men without a history of cancer who are within one year of age of ADT+ participants (PCa-) Exclusion Criteria: * Second cancer diagnosis (excluding non-invasive skin cancers) * History of stroke, transient ischemic attack, neurological disorder, or brain surgery involving tissue removal * Unable to walk without assistance * Unwilling to complete study requirements * Body weight greater than 300 pounds (DXA requirement) * Moderate-intensity physical activity ≥ 150 minutes per week * Upper and lower body strength training ≥ 2 days per week * Unable to read in English
References
Publications (0)
Data not yet available
No reference posted for this study.